Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Hires at ArcticZymes, IntegenX, GenturaDx, GeneThera

Premium

ArcticZymes has named Brent Spoth as business development manager for the Americas.

Spoth, who will work out of ArcticZymes' recently opened US office in Plymouth Meeting, Penn., joins ArcticZymes from Bioneer, where he served as an account manager. Spoth has also served as an account executive at Gemini Bio-Products; and as an account manager and field applications scientist for Promega. He holds a PhD in microbiology from the University of Virginia.


IntegenX said this week that it has appointed Bob Barrett as vice president of strategy and business development for human identity products.

Barrett will help drive the commercialization strategy for IntegenX's RapidHit 200 sample-to-profile human identification system. He joins IntegenX from Qiagen, where he served as vice president of global marketing for molecular diagnostics. Prior to this, he was vice president and general manager of the applied markets division at Applied Biosystems, now Life Technologies. Barrett has also served as vice president of global marketing at Roche Molecular Systems and as vice president of commercial operations at Chiron.


GenturaDx has named Michael Treble to its board of directors.

Treble is currently chairman and CEO of Axela. Formerly he was president of Ibis Biosciences, now part of Abbott. He has also served as president and CEO of NimbleGen, now part of Roche; and has held positions with Third Wave Technologies, Roche Diagnostics, and Abbott Diagnostics.


GeneThera said this week that it has appointed Tony Milici as interim president of Applied Genetics, a joint venture between Nutricion Avanzada and GeneThera.

Located in Monterrey, Mexico, Applied Genetics focuses on molecular testing for Johne's disease, a global and incurable disease of dairy cows, sheep, and goats caused by Mycobacterium paratuberculosis sub. Avium, or MAP. The company markets HerdCheck, a proprietary molecular diagnostic test for the disease based on the use of high-throughput robotics and real-time PCR.